Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
IO Biotech
company
About
IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.
- 1 - 10
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- €11M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Dec 23, 2014
- Number Of Employee
- 1 - 10
- Operating Status
- Active
IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-win®, enabling the activation of T cells that are specific for immune-suppressive molecules. IO Biotech has a proven track record of progressing preclinical and clinical compounds. The two lead compounds targeting IDO and PD-L1 are in clinical development and several pipeline compounds are in pre-clinical phase.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
€138M
IO Biotech has raised a total of
€138M
in funding over 2 rounds. Their latest funding was raised on
Jan 13, 2021 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 13, 2021 | Series B | €127M | 1 | — | — | Detail |
| Jan 5, 2016 | Series A | €11M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
IO Biotech is funded by 2 investors.
Lundbeckfonden Emerge
and Novo Nordisk
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Lundbeckfonden Emerge
|
— | Series B |
Novo Nordisk
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
